URGN vs NTLA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
URGN · UroGen Pharma Ltd$27.65 ▼ 12.86%
NTLA · Intellia Therapeutics$10.00 ▲ 5.04%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- URGN +2.7%
- NTLA +19.8%
Head to head
| Metric | URGN | NTLA |
|---|---|---|
| Price | $27.65 | $10.00 |
| Change today | ▼ 12.86% | ▲ 5.04% |
| Market cap | $1.36B | $1.40B |
| Return, 3 months | -40.1% | -20.4% |
| Return, year to date | +18.1% | +11.2% |
| Return, 1 year | +6.9% | +21.8% |
| P/E (TTM) | – | – |
| P/B | -10.8 | 2.3 |
| P/E percentile vs own 5y | 4th | 78th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +223.9% | -48.0% |
| Net profit growth (YoY) | +95.6% | -25.8% |
| Gross margin | 91.4% | – |
| Operating margin | -12.4% | -821.2% |
| Net margin | -26.3% | -805.7% |
| Return on equity | – | -62.6% |
| Analyst target vs. price | +125.0% | +92.0% |
| Analyst buy share | 100% | 36% |
| RSI (14) | 40 | 41 |
| 30-day volatility | 89.8% | 77.8% |
| Max drawdown, 1 year | -50.8% | -46.6% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NTLA is the largest of the group by market value.
- NTLA has returned the most over the past year.
- URGN is growing revenue fastest.
- URGN keeps the most profit per dollar of sales.
- NTLA has been the calmest stock over the last 30 days.